Fagron (FAGR) Stock Overview
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
FAGR Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Fagron NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €22.10 |
| 52 Week High | €23.85 |
| 52 Week Low | €17.54 |
| Beta | 0.33 |
| 1 Month Change | 1.61% |
| 3 Month Change | 1.61% |
| 1 Year Change | 17.55% |
| 3 Year Change | 37.01% |
| 5 Year Change | 14.63% |
| Change since IPO | 119.46% |
Recent News & Updates
Recent updates
Fagron NV's (EBR:FAGR) Intrinsic Value Is Potentially 76% Above Its Share Price
Dec 20
Fagron NV's (EBR:FAGR) Popularity With Investors Is Under Threat From Overpricing
Oct 29These 4 Measures Indicate That Fagron (EBR:FAGR) Is Using Debt Reasonably Well
Apr 08
New Compounding Services Strategy Will Drive Customer Acquisition In North America
Strategic acquisitions and improved commercial strategies are enhancing Fagron's market position, driving revenue growth, and expanding the product portfolio in key regions.Return Trends At Fagron (EBR:FAGR) Aren't Appealing
Dec 24Risks To Shareholder Returns Are Elevated At These Prices For Fagron NV (EBR:FAGR)
Oct 07Fagron NV's (EBR:FAGR) CEO Will Probably Find It Hard To See A Huge Raise This Year
May 07The Returns At Fagron (EBR:FAGR) Aren't Growing
Apr 17Is Fagron (EBR:FAGR) A Risky Investment?
Mar 15Earnings Tell The Story For Fagron NV (EBR:FAGR)
Feb 18Fagron (EBR:FAGR) Seems To Use Debt Quite Sensibly
Aug 11Be Wary Of Fagron (EBR:FAGR) And Its Returns On Capital
Jun 10Fagron (EBR:FAGR) Has Announced That It Will Be Increasing Its Dividend To €0.175
May 12An Intrinsic Calculation For Fagron NV (EBR:FAGR) Suggests It's 30% Undervalued
Apr 20Is Fagron (EBR:FAGR) A Risky Investment?
Apr 02Here's Why Fagron (EBR:FAGR) Can Manage Its Debt Responsibly
Oct 14Return Trends At Fagron (EBR:FAGR) Aren't Appealing
Jun 04Fagron (EBR:FAGR) Is Paying Out A Larger Dividend Than Last Year
May 13Is Fagron (EBR:FAGR) Using Too Much Debt?
Apr 13Slowing Rates Of Return At Fagron (EBR:FAGR) Leave Little Room For Excitement
Feb 16Fagron (EBR:FAGR) Has A Pretty Healthy Balance Sheet
Nov 18Fagron (EBR:FAGR) Is Experiencing Growth In Returns On Capital
Sep 25Are Investors Undervaluing Fagron NV (EBR:FAGR) By 45%?
Aug 30Fagron NV (EBR:FAGR) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 08Is Fagron (EBR:FAGR) A Risky Investment?
Jun 15Fagron NV (EBR:FAGR) Shares Could Be 49% Below Their Intrinsic Value Estimate
May 29The Returns At Fagron (EBR:FAGR) Aren't Growing
May 03Shareholder Returns
| FAGR | BE Healthcare | BE Market | |
|---|---|---|---|
| 7D | 4.2% | 1.2% | 4.2% |
| 1Y | 17.6% | 3.8% | 24.3% |
Return vs Industry: FAGR exceeded the Belgian Healthcare industry which returned 0.4% over the past year.
Return vs Market: FAGR underperformed the Belgian Market which returned 19.4% over the past year.
Price Volatility
| FAGR volatility | |
|---|---|
| FAGR Average Weekly Movement | 3.7% |
| Healthcare Industry Average Movement | 5.6% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in BE Market | 7.3% |
| 10% least volatile stocks in BE Market | 2.6% |
Stable Share Price: FAGR has not had significant price volatility in the past 3 months compared to the Belgian market.
Volatility Over Time: FAGR's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 4,193 | Rafael Padilla | www.fagron.com |
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort; and Cleoderm, a topical cream used for the compounding of personalized dermatological treatments.
Fagron NV Fundamentals Summary
| FAGR fundamental statistics | |
|---|---|
| Market cap | €1.62b |
| Earnings (TTM) | €91.02m |
| Revenue (TTM) | €952.17m |
Is FAGR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FAGR income statement (TTM) | |
|---|---|
| Revenue | €952.17m |
| Cost of Revenue | €520.16m |
| Gross Profit | €432.01m |
| Other Expenses | €340.99m |
| Earnings | €91.02m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Jul 30, 2026
| Earnings per share (EPS) | 1.24 |
| Gross Margin | 45.37% |
| Net Profit Margin | 9.56% |
| Debt/Equity Ratio | 74.3% |
How did FAGR perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/04 16:50 |
| End of Day Share Price | 2026/04/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fagron NV is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Beatrice Fairbairn | Berenberg |
| Samuel England | Berenberg |
| Beatrice Allen | Berenberg |